Loredana Urso

Padova, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Circulating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma.

Circulating microRNAs as biomarkers for risk assessment and prognostic stratification of pleural mesothelioma.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 02, 2025

mTOR inhibition sensitizes T-ALL cells to Venetoclax through engagement of the integrated stress response.

mTOR inhibition sensitizes T-ALL cells to Venetoclax through engagement of the integrated stress response.

Journal: Signal transduction and targeted therapy
Published: April 24, 2025

Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets.

Editorial: Moving beyond the molecular mechanisms of malignant pleural mesothelioma: Cues for novel biomarkers and drug targets.

Journal: Frontiers in oncology
Published: February 10, 2023

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus.

Repurposing Verapamil to Enhance Killing of T-ALL Cells by the mTOR Inhibitor Everolimus.

Journal: Antioxidants (Basel, Switzerland)
Published: January 19, 2023

mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.

mTOR inhibition downregulates glucose-6-phosphate dehydrogenase and induces ROS-dependent death in T-cell acute lymphoblastic leukemia cells.

Journal: Redox biology
Published: January 28, 2022

The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers.

The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers.

Journal: Cancers
Published: October 11, 2021

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial.

Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 21, 2021

Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification.

Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification.

Journal: Cytokine
Published: March 10, 2021

P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment.

P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment.

Journal: Frontiers in oncology
Published: January 14, 2021

ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis.

ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis.

Journal: Frontiers in oncology
Published: November 03, 2020

Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer.

Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer.

Journal: Frontiers in oncology
Published: May 22, 2020

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.

A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.

Journal: The Lancet. Oncology
Published: May 10, 2020
Showing 1-12 of 22

Last Updated: 09/26/2026